ASCO 2026: Latest updates in mRCC
Laurie Connors speaks to ecancer about PARP inhibitors for prostate cancer.
She initially outlines how PARP, and PARP inhibitors work, as well a the history of their usage.
Laurie then explores some of the PARP inhibitors for prostate cancer that are currently approved, and what this means for treatment, but also testing of family members.
This programme has been supported by an unrestricted educational grant from Pfizer.
ASCO 2026: Latest updates in mRCC
Best practice in precision medicine for prostate cancer
Burden and trends of breast cancer worldwide: Opportunities for prevention?
New classification for identifying HR myeloma based on cytogenetic abnormalities
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
EAU 2024: Bladder cancer latest
Lung Cancer